Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults

References

• Dayton VD, Arthur DC, Gajl-Peczalska KJ, et al. L3 acute lymphoblastic leukemia. Comparison with small noncleaved cell lymphoma involving the bone marrow. Am J Clin Pathol 1994; 101: 130–139.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Xavier AC, Wahlquist AE, et al. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 2013; 121: 4861–4866.
   PubMed Web of Science ®Google Scholar
• Levine PH, Kamaraju LS, Connelly RR, et al. The American Burkitt's Lymphoma Registry: eight years' experience. Cancer 1982; 49: 1016–1022.
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large–cell lymphoma in the pre–highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23: 4430–4438.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O'Brien S, et  al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569–1580.
   PubMed Web of Science ®Google Scholar
• Magrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 1984; 63: 1102–1111.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115: 3008–3016.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008.
   Google Scholar
• Hoelzer D. Treatment of acute lymphoblastic leukemia. Semin Hematol 1994; 31: 1–15.
   PubMed Web of Science ®Google Scholar
• Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92: 1556–1564.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579–4586.
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925–934.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 2014; 165: 102–111.
   PubMed Web of Science ®Google Scholar
• Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007; 8(Suppl 2):S57–62.
   PubMedGoogle Scholar
• Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 2014; 124: 2870–2879.
   Google Scholar
• Tholouli E, Watt S, Lucas GS, et al. Stage IV adult sporadic Burkitt lymphoma/leukemia with complex bone marrow cytogenetics is associated with a very poor outcome. Blood 2009; 114: 485–486; author reply 486–487.
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Landgren O, et  al. Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010; 54: 78–84.
   PubMed Web of Science ®Google Scholar
• Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS 2010; 24: 851–856.
   PubMed Web of Science ®Google Scholar
• Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003; 98: 1196–1205.
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492–1499.
   PubMed Web of Science ®Google Scholar
• Noy A, Kaplan L, Lee JY. A Modified Dose Intensive R-CODOX-M/IVAC For HIV-Associated Burkitt and Atypical Burkitt Lymphoma (BL) Demonstrates High Cure Rates and Low Toxicity: Prospective Multicenter Phase II Trial Of The AIDS Malignancy Consortium (AMC 048). Blood 2013; 122: 639–639.
   Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. New Engl J Med 2013; 369: 1915–1925.
   PubMed Web of Science ®Google Scholar
• Schommers P, Hentrich M, Hoffmann C, et al. Survival of AIDS‐related diffuse large B‐cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol 2014; 168: 806–810.
   PubMed Web of Science ®Google Scholar
• Alwan F, He A, Montoto S, et al. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy. AIDS 2015; 29: 903–910.
   PubMed Web of Science ®Google Scholar
• Seegmiller AC, Garcia R, Huang R, et al. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol 2010; 23: 909–920.
   PubMed Web of Science ®Google Scholar
• de Souza MT, Mkrtchyan H, Hassan R, et al. Secondary abnormalities involving 1q or 13q and poor outcome in high stage Burkitt leukemia/lymphoma cases with 8q24 rearrangement at diagnosis. Int J Hematol 2011; 93: 232–236.
   PubMed Web of Science ®Google Scholar
• La Starza R, Crescenzi B, Pierini V, et al. A common 93-kb duplicated DNA sequence at 1q21.2 in acute lymphoblastic leukemia and Burkitt lymphoma. Cancer Genet Cytogenet 2007; 175: 73–76.
   PubMed Web of Science ®Google Scholar
• Garcia JL, Hernandez JM, Gutierrez NC, et al. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia 2003; 17: 2016–2024.
   PubMed Web of Science ®Google Scholar